Bayer $252 million plus hemophilia gene therapy

Source: China Council for the promotion of drugs June 23, 2014, Bayer announced that it would obtain the gene therapy project of dimension company for hemophilia treatment at the price of US $252 million, which is in phase I / IIA According to dimension CEO Tom Beck, the gene therapy uses regenx technology This technology was authorized by Professor James Wilson of the University of Pennsylvania and studied by the University of Wilson on the basis of AAV technology The treatment method is to insert the correct gene sequence into the defective gene sequence of hemophilia patients According to reports, this method has a good effect in long-term follow-up animal experiments At present, it has also achieved significant effect in some small samples of patients This is Bayer's next step in hemophilia In February 2014, Bayer announced that the achievements of the a-hemophilia drug Bay 94-9027 in the phase III study of protect achieved the expected goal Later, the company invested more than 500 million euros (about 700 million US dollars) in two factories in Wuppertal and Leverkusen, Germany, to expand the research scale of bay 94-9027 (long-acting rFVIII) and another product bay-81-8973 (plasma free rFVIII) Under the agreement with dimension, Bayer will fund dimension to develop all preclinical studies and subsequent preclinical studies for the treatment of hemophilia A Once successful, Bayer will be responsible for the final clinical phase III study, and once successful, Bayer will gain global commercial rights to this treatment Dimension will retain the ownership of hemophilia B therapy In recent years, the research on hemophilia A and hemophilia B has been paid more and more attention by major pharmaceutical companies Recently, elocate, a hemophilia a drug developed by Biogen, has just been approved by FDA The industry estimates annual sales of up to $1.5 billion It can be predicted that in the future, the competition on hemophilia therapy research will be more intense This article is edited according to the contents of e-medicine Facebook and Biovalley articles.